The honest starting point is that no one has multi-year data on this specific combination. The pivotal REDEFINE program ran to roughly 68 weeks, long enough to establish where weight loss lands and what the common adverse events look like, and far short of what would describe durability across five or ten years. Everything said about the longer arc is borrowed from the wider incretin class, where the pattern is consistent: weight holds while treatment continues, and a substantial share returns when it stops.
The REDEFINE trials characterized this combination over roughly 68 weeks, and with no dedicated withdrawal study of the combination reported, the long-term picture rests on incretin-class evidence in which participants regained about two-thirds of lost weight within a year of stopping.
The evidence horizon is measured in months rather than years. Within the roughly 68-week trial window the record is reasonably rich, covering weight trajectory, glycemic effects, adverse events, discontinuation rates, and dose tolerability under regular follow-up; beyond it the record thins fast, and a cardiovascular outcomes trial designed to run considerably longer has not yet reported. The two halves of the molecule also carry unequal history, which is where the gap actually sits.
| Criterion | Semaglutide component | Cagrilintide component |
|---|---|---|
| Years in broad clinical use | Several, across diabetes and obesity | Newer, short track record |
| Post-marketing surveillance | Established | Limited |
| Longest controlled use in combination | About 68 weeks | About 68 weeks |
| Multi-year outcome data | Extension studies reported | Not yet reported |
The longest well-characterized stretch of continuous use of this combination in a controlled setting is roughly 68 weeks, so any statement about five-year or ten-year use is extrapolation from the components rather than observation of the combination itself.
A plateau reads as failure to most people watching the scale, and that reading is the single most expensive misinterpretation in this class. Loss slows because energy balance finds a new equilibrium: a smaller body burns fewer calories, adaptive changes in metabolic rate offset part of the reduced intake, and the same appetite suppression that produced a large daily deficit early on now produces a small one. The therapeutic job changes at that point from producing loss to defending it, which is a real clinical effect even when the number stops moving.
Across the incretin class the steepest weight loss occurs in the first four to eight months and approaches a plateau around the twelve to sixteen month mark, which is roughly the point at which the pivotal trials of this combination ended.
No published withdrawal study exists for this combination, so the answer is assembled from the wider incretin class, and that literature is unusually consistent about the direction and the speed. The cardiometabolic benefit turns out to be tied to being on treatment rather than banked by having once lost weight. A minority hold a substantial share of their loss, generally those in whom durable eating patterns, resistance training, sleep, and support structures were established during the treatment period.
In the extension of the pivotal semaglutide 2.4 mg obesity trial, participants who stopped after 68 weeks regained roughly two-thirds of the weight they had lost over the following year, with blood pressure, lipid, and glycemic improvements drifting back alongside it.
The body treats a lost fifth of body weight as an emergency rather than an achievement. After significant loss, circulating ghrelin rises, satiety signals including leptin, peptide YY, and cholecystokinin fall, and resting energy expenditure drops further than the smaller body size alone would predict; studies following non-pharmacological weight loss have found these changes persisting a year or more. The two components press against that defense continuously from different directions, but neither one rewrites the weight the body is defending.
| Parameter | On treatment | After withdrawal |
|---|---|---|
| Hunger and food reward signaling | Suppressed via hypothalamic and brainstem circuits | Returns to the elevated post-loss state |
| Gastric emptying and meal termination | Slowed; satiety enhanced through amylin receptors | Reverts as drug concentration falls over weeks |
| Resting energy expenditure | Reduced with body size, and further by adaptation | Remains reduced |
| Defended body weight | Unchanged | Unchanged |
Both components override appetite signaling continuously rather than resetting the body's defended weight, so withdrawal restores the elevated hunger drive against a metabolism that is now running leaner than before the weight was lost.
Current clinical thinking treats obesity pharmacotherapy the way it treats therapy for hypertension or dyslipidemia: continued while it is working, tolerated, and still indicated, rather than run to a fixed finish line. Guidelines from major obesity and endocrine bodies describe these medicines as long-term treatments and caution explicitly that discontinuation is usually followed by regain. Indefinite in this context means reviewed at intervals, not prescribed and forgotten.
Major obesity and endocrine guidelines describe this drug class as long-term therapy continued while it remains effective, tolerated, and indicated, with discontinuation documented as usually followed by regain.
Every method of substantial weight loss costs some lean tissue, and pharmacological loss is no exception. Body composition substudies across the incretin class place the lean fraction of total weight lost broadly in line with what equivalent loss through caloric restriction produces, rather than uniquely worse, and lean mass includes more than skeletal muscle, so the raw percentage overstates the functional concern for many people. It does not overstate it for older adults, people with existing low muscle mass or sarcopenic obesity, or anyone whose intake falls very low, where lost function is harder to rebuild than the fat was to lose.
Body composition substudies across the incretin class report that roughly a quarter to two-fifths of total weight lost is lean mass, and the published countermeasures are protein intake of at least 1.2 grams per kilogram daily plus resistance training on at least two days a week.
Tolerability follows a fairly predictable arc, which is exactly why dosing is escalated gradually rather than started at target. In the pivotal trials of this combination, gastrointestinal events were the dominant adverse-event category and most were transient, though a minority of participants discontinued because of them. What changes with duration is not only severity but the kind of concern that becomes relevant.
Gastrointestinal events were the dominant adverse-event category in the pivotal trials of this combination and most were transient, while gallstones were reported more often on semaglutide than on placebo even after the degree of weight loss was accounted for.
Long-term use is described in practice as a supervised relationship rather than a standing prescription, and the reason is arithmetic as much as clinical: falling weight changes the correct dose of everything else a person takes. Documented reassessment at defined points is also what makes a considered decision to continue, adjust, or stop possible, instead of the drift into an unplanned interruption that tends to produce the worst outcomes.
Published practice describes contact every four to eight weeks during dose escalation and review at roughly three to six month intervals once maintenance dosing is stable, with concurrent insulin, sulfonylurea, and antihypertensive doses frequently requiring reduction as weight falls.
The most valuable feature of the treatment period is not the weight it removes but the window it opens. While appetite is pharmacologically suppressed, behaviors that normally take constant effort become comparatively easy to install, and those habits are the assets that remain if treatment is ever reduced or stopped. People who spend that window relying on the drug alone arrive at any future stop with nothing in place.
Observational maintenance registries link sustained weight maintenance to roughly 200 to 300 minutes of moderate activity weekly plus resistance training two to three times a week, and structured dietitian or behavioral contact continued past the plateau outperforms medicine alone.
Cost stops being a one-time purchase decision the moment treatment is understood as long term. The relevant question is not whether a month is affordable but whether several years are, because an interruption forced by access produces the same regain physiology as a decision to quit. Against that sits the cost of the untreated condition, which is real but harder to see, spanning diabetes management, cardiovascular events, joint disease, sleep apnea, and reduced work capacity.
An interruption caused by formulary exclusion, a lapsed body mass index criterion, or constrained supply produces the same regain physiology as a decision to quit, which places continuity of access alongside efficacy and tolerability as a clinical variable.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
